Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effectiveness and Safety of Rivaroxaban Compared With Apixaban in Cancer-Associated Venous Thromboembolism: A Head-to-Head (H2H) Analysis of the United States Cohort of the Observational Study in Cancer Associated Thrombosis for Rivaroxaban

Next Previous
Search
Trial Profile

Effectiveness and Safety of Rivaroxaban Compared With Apixaban in Cancer-Associated Venous Thromboembolism: A Head-to-Head (H2H) Analysis of the United States Cohort of the Observational Study in Cancer Associated Thrombosis for Rivaroxaban

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 18 Jan 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Apixaban (Primary) ; Rivaroxaban (Primary)
  • Indications Pulmonary embolism; Venous thromboembolism
  • Focus Therapeutic Use
  • Acronyms H2H-OSCAR-US
  • Sponsors Bayer

    • Most Recent Events

    • 13 Dec 2022 Results assessing whether rivaroxaban associated with comparable effectiveness and safety as apixaban for CAT treatment , presented at the 64th American Society of Hematology Annual Meeting and Exposition
    • 25 Oct 2022 Status changed from active, no longer recruiting to completed.
    • 24 Aug 2022 Planned End Date changed from 31 Aug 2022 to 31 Oct 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top